Literature DB >> 29122657

Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.

Fumie Igari1, Eiichi Sato2, Yoshiya Horimoto1, Yuka Takahashi1, Tatsuya Isomura3, Atsushi Arakawa4, Shigehisa Kitano5, Mitsue Saito1.   

Abstract

Invasive ductal carcinomas of breast with marked stromal lymphocytic infiltration have come to be classified as lymphocyte-predominant breast cancer (LPBC) because it obtains high pathological complete response rates with neoadjuvant chemotherapy. Medullary carcinoma (MC), which is independent from LPBC, is a rare histological subtype of invasive breast carcinoma accompanied by abundant lymphoplasmacytic infiltration as LPBC. Although MC shows marked cellular and structural atypia, it usually has a favorable outcome. It is occasionally difficult to distinguish MC from LPBC because both subtypes have nonspecific morphological features according to the present diagnostic criteria. Herein, we adopted multiplexed fluorescent immunohistochemistry to perform quantitative and simultaneous analyses of tumor-infiltrating lymphocytes (TILs) considering their spatial distribution and examined focal immune reaction differences between MC and LPBC. We found that CD8+ TILs are predominant in the intratumoral region, whereas CD4+ TILs are less common in MC. In non-luminal-type cancers, the numbers of stromal and intratumoral CD8+ TILs were significantly higher in MC than in LPBC. Stratified analyses by CD4+ TIL subsets showed robust infiltration of intratumoral CD8+ TILs in non-luminal-type MC even in suppressive environments, such a low T helper 1-to-regulatory T cell ratio. Our results suggest that extensive intratumoral CD8+ TIL infiltration might well be a promising biomarker for distinguishing MC from LPBC, especially in non-luminal-type cancers. Intratumoral CD8+ TILs and nonluminal intrinsic subtypes may serve as diagnostic characteristics allowing reliable histological criteria to be established for reproducibly diagnosing MC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer immunology; Immunohistochemistry; Multiplex fluorescent labeling; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 29122657     DOI: 10.1016/j.humpath.2017.10.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.

Authors:  Daiki Ikarashi; Shigehisa Kitano; Takashi Tsuyukubo; Kazumasa Takenouchi; Takayuki Nakayama; Hiroko Onagi; Asumi Sakaguchi; Makiko Yamashita; Hidenori Mizugaki; Shigekatsu Maekawa; Renpei Kato; Yoichiro Kato; Tamotsu Sugai; Tetsuya Nakatsura; Wataru Obara
Journal:  Br J Cancer       Date:  2021-11-15       Impact factor: 9.075

2.  Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.

Authors:  Daigoro Takahashi; Motohiro Kojima; Toshihiro Suzuki; Motokazu Sugimoto; Shin Kobayashi; Shinichiro Takahashi; Masaru Konishi; Naoto Gotohda; Masafumi Ikeda; Tetsuya Nakatsura; Atsushi Ochiai; Masato Nagino
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

3.  Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC.

Authors:  Daiki Ikarashi; Tamio Okimoto; Takehito Shukuya; Hiroko Onagi; Takuo Hayashi; Sara L Sinicropi-Yao; Joseph M Amann; Tetsuya Nakatsura; Shigehisa Kitano; David P Carbone
Journal:  JTO Clin Res Rep       Date:  2021-09-20

4.  Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer.

Authors:  Bei Li; Rongxin Geng; Qi Wu; Qian Yang; Si Sun; Shan Zhu; Zhiliang Xu; Shengrong Sun
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

5.  Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.

Authors:  Koji Yoshino; Takayuki Nakayama; Ayumu Ito; Eiichi Sato; Shigehisa Kitano
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

6.  Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.

Authors:  Ken Imaizumi; Toshihiro Suzuki; Motohiro Kojima; Manami Shimomura; Naoki Sakuyama; Yuichiro Tsukada; Takeshi Sasaki; Yuji Nishizawa; Akinobu Taketomi; Masaaki Ito; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-12-18       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.